Laurus Labs Share Price Hit Record High After Q1 FY27 Results: Net Profit Jumps 125% YoY

Laurus Labs share price (NSE: LAURUSLABS) gained around 2% during intraday trading on July 24, 2026, and touched a new all-time high of ₹1,603 after the company reported a sharp rise in its first-quarter earnings for FY27.

The stock has delivered strong returns, rising nearly 62% in FY27 so far, compared to a 6.6% gain in the Nifty 50 index. It has also almost doubled from its 52-week low of ₹810, recorded in August 2025.

Laurus LabsQ1 FY27 Financial Performance

Laurus Labs reported a strong set of results for the quarter ended June 30, 2026.

• Net profit rose 124.7% year-on-year to ₹361.99 crore, compared to ₹161.08 crore in the same quarter last year.
• Total income increased 28.8% YoY to ₹2,035.49 crore, up from ₹1,580 crore.
• EBITDA climbed to ₹644 crore, compared to ₹389 crore a year ago.
• Earnings per share (EPS) improved to ₹6.8, from ₹3 in Q1 FY26. 

What Drove the Strong Performance?

According to the company, the strong quarterly performance was supported by:

• Higher commercial deliveries in the CDMO (Contract Development and Manufacturing Organisation) business.
• Continued strong demand for its Affordable Medicines portfolio.
• Expansion of its integrated manufacturing capabilities.
• Ongoing focus on specialised solutions for global pharmaceutical clients. 

The company said it delivered its highest-ever quarterly revenue, along with improved profitability.

Strategic Developments

During the quarter, Laurus Labs also announced several important developments to support its long-term growth plans:

• Signed an agreement to in-license two Antibody Drug Conjugates (ADCs).
• Secured the final handover of a new land parcel to support future expansion.
• Continued strengthening its specialised pharmaceutical capabilities. 

Board Update

The company also informed stock exchanges that Independent Director Dr. Rajesh Koshy Chandy will retire from the Board with effect from the close of business on July 26, 2026.

Read More: Dr. Reddy's Laboratories Share Price Falls Over 2% After Q1 FY27 Earnings Results: Total Income Down 4.6% YoY!

Conclusion

Laurus Labs reported a strong start to FY27, with record quarterly revenue, a sharp increase in profit, and higher operating earnings. Growth in its CDMO business, steady demand for affordable medicines, and strategic investments in new technologies and infrastructure have strengthened its long-term growth outlook. 

For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.